Royalty Pharma stock is trading -20.82% below its average target price of $44.86 after marking a 1.1% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $37.0 to $55.0 per share.
Royalty Pharma's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.9%. The stock's short ratio is 5.47. The company's insiders own 8.73% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 82.5%. In conclusion, we believe there is positive market sentiment regarding Royalty Pharma.
Institutions Invested in Royalty Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Morgan Stanley | 11% | 46,604,103 | $1,655,377,759 |
| 2025-06-30 | FMR, LLC | 9% | 40,357,821 | $1,433,509,820 |
| 2025-06-30 | Vanguard Group Inc | 8% | 36,377,678 | $1,292,135,139 |
| 2025-06-30 | Blackrock Inc. | 6% | 25,428,856 | $903,232,976 |
| 2025-06-30 | Capital International Investors | 5% | 21,880,620 | $777,199,632 |
| 2025-06-30 | BAILLIE GIFFORD & CO | 4% | 18,020,455 | $640,086,569 |
| 2025-06-30 | Swedbank AB | 3% | 12,157,470 | $431,833,339 |
| 2025-06-30 | State Street Corporation | 2% | 10,194,938 | $362,124,202 |
| 2025-06-30 | Geode Capital Management, LLC | 2% | 8,176,504 | $290,429,425 |
| 2025-06-30 | Caledonia (Private) Investments Pty Ltd | 1% | 6,444,729 | $228,916,777 |
